BIOGEN INC. (BIIB) closed fiscal year 2025 with a gross margin of 75.7 % and a net margin of 13.1 %.
BIOGEN INC. (BIIB) closed fiscal year 2025 with a gross margin of 75.7 % and a net margin of 13.1 %. The same year shows an EBITDA margin of 26.7 % and an EBIT margin of 18.8 %. The free cash flow margin was 20.7 %. Against the previous year the gross margin moved −0.4 pp and the net margin −3.8 pp. Across the period the gross margin ranges between 74.2 % in 2023 and 91.5 % in 2010. The series covers 19 fiscal years, from 2007 to 2025. Margins are expressed as a percentage of net revenue and are derived from the same figures as the income statement, taken from as-reported SEC EDGAR filings, with no restatements or adjustments of our own.
Fiscal year end: December
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin (%) | 89.43 % | 90.19 % | 91.27 % | 91.51 % | 90.76 % | 90.11 % | 87.63 % | 87.93 % | 88.48 % | 87.08 % | 86.72 % | 86.50 % | 86.40 % | 86.57 % | 80.79 % | 77.61 % | 74.24 % | 76.12 % | 75.69 % |
| EBITDA margin (%) | 36.58 % | 40.89 % | 39.37 % | 34.02 % | 41.27 % | 40.27 % | 43.96 % | 48.03 % | 51.02 % | 50.96 % | 52.36 % | 48.61 % | 52.21 % | 37.24 % | 30.31 % | 39.34 % | 21.42 % | 30.21 % | 26.71 % |
| EBIT margin (%) | 24.59 % | 29.62 % | 29.59 % | 26.48 % | 34.16 % | 33.64 % | 36.29 % | 40.94 % | 45.44 % | 45.00 % | 43.55 % | 43.77 % | 48.98 % | 33.84 % | 25.87 % | 34.24 % | 16.39 % | 23.25 % | 18.83 % |
| Net margin (%) | 20.12 % | 19.11 % | 22.16 % | 21.31 % | 24.45 % | 25.02 % | 26.86 % | 30.25 % | 32.95 % | 32.34 % | 20.69 % | 32.93 % | 40.96 % | 29.76 % | 14.17 % | 29.95 % | 11.81 % | 16.87 % | 13.07 % |
| FCF margin (%) | 23.16 % | 31.40 % | 20.77 % | 30.78 % | 30.10 % | 29.46 % | 30.28 % | 27.35 % | 30.44 % | 34.69 % | 30.01 % | 40.27 % | 45.65 % | 28.30 % | 30.79 % | 11.25 % | 12.91 % | 28.13 % | 20.73 % |
